Articles tagged with Tuberculosis
Groundbreaking progress in TB vaccine development and therapeutic innovations offer hope to curb the disease's devastating impact, with multi-antigen vaccines and mRNA-based platforms showing promise.
A new study compares the allosteric regulation of Escherichia coli and Mycobacterium tuberculosis cAMP receptor proteins, revealing distinct regulatory mechanisms despite structural resemblance. The findings suggest species-specific control over bacterial gene regulation and have potential implications for drug development.
Researchers developed a next-generation technology, MycoBCP, using artificial intelligence to screen for antimicrobial compound candidates. This method has already vastly accelerated the team's TB research capabilities and helped identify optimal candidate compounds for drug development.
A major clinical trial has identified three new safe and effective regimens for treating drug-resistant tuberculosis, offering faster, safer, and more accessible care. The new treatments show promise in reducing treatment duration and side effects, making them a significant breakthrough in the fight against this infectious disease.
A new TB risk scoring tool has been developed to assess patients for potential TB infections, enabling accurate decisions on isolation precautions. The tool has been validated and is now in use at all MGB sites, positively impacting patient care and clinician workflows.
A clinical trial published in the New England Journal of Medicine showed that levofloxacin substantially reduced the risk of developing drug-resistant tuberculosis. The study found that levofloxacin reduced the risk of multidrug-resistant TB in adults and adolescents by 45 percent, and also significantly reduced the risk among family m...
A new self-destructing vaccine provides improved safety and protection against TB in macaque monkeys, outperforming the standard BCG vaccine. The 'kill switch' mechanism eliminates the risk of accidental infection, offering a safer vaccination option for immunocompromised individuals.
The report highlights a persistently high burden of TB in low- and middle-income countries, with 10.8 million new cases reported in 2023. It emphasizes the need for increased funding, improved diagnostics, and effective treatment regimens to combat drug-resistant TB.
A study found that over a quarter of TB drug-resistant strains result from patient-to-patient transmission, highlighting the need for improved surveillance and infection control. The emergence of highly drug-resistant TB poses a significant challenge to global health efforts.
A landmark study by Barcelona Institute for Global Health found that Brazil's Bolsa Família Program reduced TB cases and deaths among extreme poverty, indigenous groups, and improved healthcare access. The program's effects were stronger among the poorest and indigenous populations, with a 50-60% decrease in TB cases.
A new system can quickly identify emerging virus variants and provide information on their genetic changes, helping to understand why they spread differently in human populations. This enables the development of more effective vaccines and targeted treatments for diseases such as flu, COVID, and tuberculosis.
John Howington, MD, MBA, FCCP, is the new President of CHEST, succeeding Neil S. Freedman, who will be President-Elect in 2026. Dr. Howington has extensive leadership experience and has published over 49 research publications.
A University of Toronto study discovered a new communication pathway between the gut and lung, highlighting the role of a little-known protozoan in shaping immune responses. The study found that this microbe can worsen airway inflammation in allergic asthma but provide protection against respiratory infections.
A new study estimates that India will see over 62.4 million cases of tuberculosis in the next two decades, posing a significant burden on the country's health and economy. Scaling up existing treatment regimens could generate at least $28 billion in GDP gains, highlighting the need for increased investment in TB control measures.
Researchers identified five fungi species with toxic effects against the bacterium, which disrupts cellular levels of thiols essential for bacterial survival. The findings support a strategy for developing treatment-shortening drugs by targeting biological processes maintaining thiol levels.
World health leaders outlined policy recommendations to tackle TB among refugee and migrant populations, leveraging successful experiences from regional countries. The report's ten strategies aim to guide stakeholders worldwide in achieving TB elimination for all.
Researchers at Tufts University discovered that TB bacteria maintain a consistent growth rate throughout their life cycle, defying expectations. The study also reveals new growth behaviors of TB bacteria, including the ability to grow from either end after division.
Researchers have uncovered why a relatively new antibiotic for tuberculosis works against multidrug-resistant strains by identifying deficiencies in a critical enzyme. This discovery could lead to improved treatments and drug development strategies, potentially allowing for lower doses or shorter treatment times.
Researchers identified a genetic weakness in drug-resistant Mycobacterium tuberculosis, allowing them to develop targeted drugs. This technology has the potential to combat other drug-resistant pathogens and prevent their spread.
A research team led by Dr. Bernd Meibohm is working on developing new treatments for tuberculosis that require fewer pills, shorter treatment periods, and reduce the risk of resistance. They aim to replace linezolid with Spectinamide 1810, a safer alternative that can be administered directly to the lungs.
A new study published in The Lancet Child & Adolescent Health found that children living in areas with a high burden of tuberculosis have a consistently high annual risk of developing TB infection throughout childhood. By age 10, over 10% of children developed TB disease.
Researchers discovered that tuberculosis alters liver metabolism and can push patients towards metabolic disease like diabetes. The study suggests undiagnosed TB could be a significant contributor to metabolic health issues.
Researchers at Texas Biomedical Research Institute developed a human cell culture model of alveolar macrophages, which helped make a key finding about the role of tumor necrosis factor (TNF) in tuberculosis (TB). The study found that TNF is critical to protect against TB but not other infectious diseases.
A new study has discovered a novel semi-synthetic compound derived from natural compounds that exhibits potent activity against Mycobacterium tuberculosis, including multi-drug resistant strains. The compound, BPD-9, provides a promising chemical scaffold for developing new anti-tuberculosis drugs.
African wormwood, a plant used for centuries to treat various illnesses, contains a compound that can kill the bacteria causing tuberculosis. Researchers have identified this compound, an O-methylflavone, as effective against both active and inactive states of the mycobacterium.
Researchers at Texas Biomedical Institute have developed a TB therapy that does not interfere with combined antiretroviral therapy (cART) in patients with HIV. The host-directed therapy blocks an immune system protein and has shown improved control of TB when used with antibiotics.
After analyzing human immune cells and TB patients, researchers found that TCA metabolism plays a crucial role in DNA methylation. Adding an inhibitor of TCA activation reduced detrimental marks, suggesting epigenetic healing is possible. This discovery may lead to new treatment strategies for infectious diseases.
A recent study found that racial and ethnic tuberculosis (TB) disparities among US-born persons can result in significant long-term health consequences. The research indicates that these disparities can have substantial effects on the economy as well, potentially affecting TB elimination goals within the US.
Researchers identified a genetic cause of TNF deficiency, which incapacitates a specific immune process in the lungs, leading to targeted and severe illness. This finding may upend long-held assumptions about the immune system and have far-reaching clinical implications.
Researchers discovered a non-virulent bacterium, Mycobacterium spongiae, that shares 80% of its genetic material with M. tuberculosis, shedding light on the disease's origins. The study provides valuable insights into the evolution and virulence of TB.
A subset of CD4 T cells create an anti-inflammatory environment within the lung tissue, protecting against TB reinfection by limiting bacterial growth and disease severity. The discovery complements previous research on protective immune T cells in controlling TB infection, suggesting a potential key to improving existing vaccines.
A study analyzing 5.5 million EU/EEA infectious disease cases over 10 years found significant sex differences in notified male versus female cases for several diseases. The proportion of males ranged from 40-45% for pertussis and Shiga toxin-producing Escherichia coli infections to 75-80% for HIV/AIDS.
Researchers found that macrophages induce cancer cell apoptosis and then eat away dead cells after BCG vaccine injection in a new animal model. This breakthrough could lead to more effective bladder cancer treatments.
Researchers found that close household contacts of people diagnosed with geographically restricted TB strains had a lower rate of infection and active TB disease compared to those exposed to widespread lineages. This suggests a shared evolution between humans and microbes, amplifying the risk for infection.
A new study by UC Davis researchers found that male gender and residency in large towns are the strongest risk factors for active TB progression in South Africa. Higher socioeconomic status, age, and migration history also impact active TB risk.
Researchers have identified a group of molecules called callyaerins that can act against tuberculosis by targeting a specific membrane protein of the bacterium Mycobacterium tuberculosis. These substances inhibit bacterial growth without affecting human cells, offering a promising new approach to treating the disease.
Human lung organoids can form lifelike models for tuberculosis infection, enabling the testing of anti-tuberculosis drugs. These models may also facilitate the development of host-directed therapies.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.
Researchers at Butantan Institute and collaborators developed a more potent version of the BCG vaccine, which protects against tuberculosis by inducing a strong immune response. The new formulation protected animals for a significantly longer period than conventional BCG.
Researchers at the University of the Witwatersrand have developed a modified BCG vaccine that shows enhanced protection against tuberculosis in mice. The new vaccine candidate could potentially replace or boost existing TB vaccines, providing a novel solution to the global health crisis.
Researchers have designed a novel 3D hydrogel culture system that accurately mimics the mammalian lung environment, allowing for the study of tuberculosis bacteria infection and therapeutics. The system successfully tracks infection progression and demonstrates the efficacy of pyrazinamide in clearing out TB bacteria.
Scientists have developed a new method to detect antibiotics in finger sweat, showing high accuracy for tuberculosis treatment monitoring. The technique allows for less invasive testing, making it easier to monitor treatment and preventing drug-resistant TB.
The American College of Chest Physicians' CHEST Critical Care and CHEST Pulmonary journals have been indexed with the Directory of Open Access Journals (DOAJ), enhancing their open access content's accessibility and usage. The indexation is attributed to strong editorial boards led by Hayley Gershengorn and Matthew Miles.
A new study suggests that countries should prioritize tuberculosis treatment for exposed individuals with evidence of TB infection, regardless of age—except in high-burden settings, where all exposed individuals should be considered for treatment. Preventive treatment can stop latent TB infections from developing into deadly TB disease.
New therapies aim to strengthen the body's immune responses and restore antimicrobial functions to combat TB. Researchers have identified small molecule compounds that reduce Mtb growth inside immune cells by up to 50-75%, suggesting a potential complement to standard therapy.
Researchers found that undernourished household contacts were three times more likely to progress to TB disease than well-nourished individuals. The study suggests that undernutrition fails to contain the infection when it occurs, leading to increased risk of severe illness and death.
Researchers uncover how tuberculosis infection drives excessive inflammation in the lungs by activating neutrophils. Targeting neutrophils could lead to new therapies for TB treatment, potentially reducing antibiotic-resistant cases.
A study of tens of thousands of individuals found that post-TB lung disease is a significant global challenge. TB survivors experience restrictive lung damage and airflow obstruction, reducing their ability to breathe efficiently and increasing the risk of cardiovascular and respiratory diseases.
A study found that structural racism is largely to blame for disparities in tuberculosis (TB) incidence among the U.S.-born population. Researchers analyzed national TB registry data and found that TB incidence ratios were higher for certain racial and ethnic groups, with greater relative disparities among females.
A population-wide observational study found an association between tuberculosis (TB) and a higher incidence of various cancers. TB patients were more likely to be diagnosed with lung, blood, gynaecological, colorectal, thyroid, oesophagus, and stomach cancers compared to the general population.
A new study finds that BCG vaccination reduces TB transmission in cattle by almost 90%. Vaccinated cows also develop significantly fewer visible signs of TB than unvaccinated ones. The vaccine has the potential to control bovine tuberculosis and put herds on a pathway towards elimination.
A new study published in Microbiology Spectrum shows that an enzymatic cocktail can effectively kill a variety of mycobacterial species, including those causing tuberculosis. The research delivers the enzymes inside host macrophages where mycobacteria grow, increasing efficacy and reducing toxicities associated with current treatments.
Researchers at Massachusetts General Hospital successfully repurposed approved drugs to improve drug delivery to tuberculosis bacteria, promoting anti-bacterial host responses and improving health outcomes. The study found that combining bevacizumab and losartan enhanced TB drug delivery and reduced bacterial burden in rabbits with TB.
Researchers have developed new recommendations for optimizing TB screening programs in low-incidence countries. Screening high-risk groups, such as migrants and vulnerable populations, is a cost-effective approach that detects the disease early and prevents transmission.
Researchers have identified a combination of medications that may improve blood flow within granulomas, benefiting drug delivery and reducing bacterial burden in tuberculosis-infected rabbits. The study leverages decades of cancer research to study tuberculosis-affected lung tissue and improves treatment.
A systematic review by Gogichadze et al. suggests that active pulmonary TB screening programs targeting vulnerable populations in low-TB-incidence countries are cost-effective. The authors conclude that screening immigrants and other high-risk groups is a viable approach to detecting latent infections.
Researchers have developed a new framework for classifying tuberculosis (TB) that replaces the traditional binary approach with four disease states: clinical, subclinical, infectious, and non-infectious. The International Consensus for Early TB (ICE-TB) framework aims to improve diagnosis and treatment of early-stage TB, which has hist...
Scientists have discovered six proteins that can accurately diagnose tuberculosis (TB). The breakthrough study paves the way for a simple blood test to detect the bacteria, which could prevent millions of cases annually. TB is the world's deadliest infectious disease, killing over one million people each year.
Tulane University researchers have developed a CRISPR-based platform for diagnosing nontuberculous mycobacteria (NTM) infections, allowing for accurate results in as little as two hours. The blood test can identify over 93% of patients with an NTM infection, enabling rapid treatment plans and reducing the risk of complications.
Research on over 600,000 TB cases reveals 80% have no persistent cough, delaying diagnoses and transmission, with high infection rates among symptomless individuals. The study suggests rethinking current diagnostic practices for more effective TB identification.